author-photo

Margaret Gamalo

Eli Lilly and Company

12

Papers

358

Citations

Citation Trend

Filter By

Papers (5) Sort By

Journal Conference Others

Baricitinib in patients with moderate-to-severe atopic dermatitis: Results from a randomized monotherapy Phase 3 trial in the United States and Canada (BREEZE-AD5).

2021 Journal of The American Academy of Dermatology
Show All
- Source
- Cite
- Save
Citations (11)
Discrete Time Multi-State Model with Regime Switching for Modelling COVID-19 Disease Progression and Clinical Outcomes

2021
Show All
- Source
- Cite
- Save
Citations (2)
Statistical Opportunities to Accelerate Development for COVID-19 Therapeutics

2020 Statistics in Biopharmaceutical Research
Show All
- Source
- Cite
- Save
Citations (4)
Efficacité et sécurité du baricitinib associé à des corticostéroïdes topiques (TCS) dans le traitement de la dermatite atopique (DA) modérée à sévère : étude de phase 3 de 16 semaines en double aveugle, randomisée et contrôlée vs placebo (BREEZE-AD7)

2020 Annales De Dermatologie Et De Venereologie
Show All
- Source
- Cite
- Save
Citations (0)
15054 Impact of baricitinib on patient-reported skin symptoms, itch, and quality of life in adult patients with moderate to severe atopic dermatitis and an inadequate response to topical therapies from phase 3 trials BREEZE-AD1 and BREEZE-AD2

2020 Journal of The American Academy of Dermatology
Show All
- Source
- Cite
- Save
Citations (0)